Investor updates Keyword Search Clear 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Published on: 22 December 2016 Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study Roche today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to ... more Published on: 21 December 2016 Positive Phase III results for Roche’s investigational medicine OCREVUS® (ocrelizumab) published in New England Journal of Medicine Roche announced today that data from three Phase III studies of its investigational medicine OCREVUS® (ocrelizumab)– the OPERA I and OPERA II studies in relapsing multiple sclerosis (RMS) and the ... more Published on: 20 December 2016 FDA extends review of application for OCREVUS™ (ocrelizumab) Roche announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics Licence Application (BLA) of ... more Published on: 16 December 2016 CHMP recommends EU conditional approval of Roche’s Alecensa (alectinib) for people with previously treated ALK-positive NSCLC Roche announced today that the European Medicines Agency (EMA) for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Alecensa® (alectinib) for the treatment of ... more Published on: 8 December 2016 Roche announces European approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia Roche announced today that the European Commission has granted conditional marketing approval for Venclyxto™ (venetoclax) for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of ... more Published on: 7 December 2016 Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin ... more Published on: 5 December 2016 Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan Roche today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva®/Gazyvaro® (obinutuzumab) plus chemotherapy followed by Gazyva/Gazyvaro alone head-to-head against ... more Published on: 5 December 2016 Changes in Roche Board of Directors At its December meeting, the Board of Directors (BoD) of Roche Holding decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 14 March 2017. more Published on: 22 November 2016 Reminder: Invitation to Roche Analyst Event at ASH 2016 We are pleased to invite you to an analyst briefing to discuss data presented on Roche Group’s hematology portfolio at the American Society of Hematology Annual Meeting (ASH) in San Diego (3 – 6 ... more Published on: 15 November 2016 Roche launches imCORE, a global network of cancer immunotherapy centers of excellence Roche today launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the world’s leading scientific and clinical experts in ... more Published on: 12 November 2016 Phase III GiACTA study shows Roche’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis Roche today announced positive results from the phase III GiACTA study, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). more Published on: 7 November 2016 Roche announces initiation of two phase III pivotal trials in melanoma based on results of studies combining targeted and immunotherapy treatment approaches; early data presented at the International Congress of the Society for Melanoma Research Roche announced results from two early cancer immunotherapy studies at the International Congress of the Society for Melanoma Research (SMR). more Published on: 3 November 2016 Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting Roche announced today that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting ... more Published on: 2 November 2016 Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting Roche today announced that new data from Actemra®/RoActemra® and Rituxan®/MabThera® will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health ... more Published on: 31 October 2016 Invitation to Roche Analyst Event at ASH 2016 We are pleased to invite you to an analyst briefing to discuss data presented on Roche Group’s hematology portfolio at the American Society of Hematology Annual Meeting (ASH) in San Diego (3 – 6 ... more Published on: 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increased 4% to CHF 37.5 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 29.1 billion, driven by demand for breast cancer medicines Perjeta and Herceptin as well as for ... more Published on: 19 October 2016 FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have ... more Published on: 17 October 2016 FDA approves Lucentis (ranibizumab injection) prefilled syringe Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. more Published on: 14 October 2016 Roche announces CHMP recommendation for EU approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto™ (venetoclax) for the treatment of people with chronic lymphocytic ... more Published on: 13 October 2016 Reminder: Invitation to Roche’s 9 Months Sales 2016 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Thursday, 20th October 2016. more Published on: 11 October 2016 FDA grants priority review to Lucentis (ranibizumab injection) supplemental biologics license application for myopic choroidal neovascularization Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Lucentis® (ranibizumab ... more Published on: 9 October 2016 Roche’s TECENTRIQ (atezolizumab) shows significant survival advantage compared to chemotherapy regardless of PD-L1 status in a specific type of lung cancer in Phase III study Roche today announced data from the positive, pivotal Phase III OAK study of TECENTRIQ® (atezolizumab) at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting in Copenhagen, Denmark. more Published on: 5 October 2016 FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra/RoActemra® (tocilizumab) for giant cell arteritis (GCA), a ... more Published on: 4 October 2016 Save the date: Roche Analyst Event at ASH 2016 We are pleased to invite you to an analyst briefing to discuss data presented on Roche Group’s hematology portfolio at the American Society of Hematology Annual Meeting (ASH) in San Diego (3 – 6 ... more Published on: 4 October 2016 US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC Roche announced today that it has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib). more Published on: 3 October 2016 First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Roche today announced that new results from studies with its approved or investigational medicines across more than 20 cancer types will be presented during the European Society for Medical Oncology ... more Published on: 22 September 2016 Invitation to Roche's Third Quarter Sales 2016 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Thursday, 20th October 2016. more Published on: 14 September 2016 Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented ... more Published on: 8 September 2016 Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Index for the eighth year running For the eighth consecutive year, Roche has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry of the Dow Jones Sustainability Index ... more Published on: 1 September 2016 Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy Roche today announced positive results for TECENTRIQ® from the Phase III study, OAK. more Published on: 26 August 2016 Anti-Cancer Agent “Xeloda®”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer” more Published on: 23 August 2016 Roche launches innovative Accu-Chek Guide blood glucose monitoring system, which makes every step of testing easy Roche today announced the launch of the Accu-Chek® Guide, the next-generation blood glucose monitoring system. more Published on: 28 July 2016 Roche’s emicizumab continued to show promising safety and efficacy profile in long-term study in people with severe haemophilia A Roche announced yesterday new data for investigational haemophilia medicine emicizumab (ACE910) at the World Federation of Hemophilia 2016 World Congress. more Published on: 27 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more Published on: 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% at constant exchange rates, 6% in Swiss francs more Published on: 19 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more Published on: 18 July 2016 Roche provides update on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma Roche today announced that the phase III GOYA study evaluating Gazyva®/Gazyvaro® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated diffuse large B-cell lymphoma ... more Published on: 14 July 2016 Reminder: Invitation to Roche's Half Year Results 2016 Roche will publish its Half Year Results for 2016 prior to the opening of the Swiss Stock Exchange on 21st July, 2016. more Published on: 5 July 2016 Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more Published on: 28 June 2016 Roche's marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Roche announced today that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of OCREVUS® (ocrelizumab) for the treatment of relapsing multiple ... more Published on: 23 June 2016 Invitation to Roche's Half Year Results 2016 Roche will publish its Half Year Results for 2016 prior to the opening of the Swiss Stock Exchange on 21st July, 2016. more Published on: 20 June 2016 Roche launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing Roche announced today that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark. more Published on: 16 June 2016 Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular ... more Published on: 8 June 2016 Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with ... more Published on: 7 June 2016 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more Published on: 6 June 2016 Phase III study shows Roche's Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA) Roche today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). more Published on: 5 June 2016 Roche’s cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer Roche, today announced that in a Phase II study, IMvigor210, Tecentriq® (atezolizumab) shrank tumours (objective response rate, ORR) in 24 percent (n=28) of people with locally advanced or metastatic ... more Published on: 4 June 2016 Roche showcases three distinct combinations for cancer immunotherapy treatment across a broad range of cancers Roche is presenting data from across its cancer immunotherapy pipeline highlighting its multipronged combination approach to cancer immunotherapy treatment. more Published on: 4 June 2016 Roche's Tecentriq® (atezolizumab) shows increasing overall survival benefit in updated clinical data analysis for people with specific type of advanced lung cancer Roche will today present updated survival data from the phase II study POPLAR, in people with previously treated advanced non-small cell lung cancer (NSCLC). more Published on: 31 May 2016 Roche's subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia Roche announced today that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera® (rituximab) for people with previously untreated and relapsed/refractory chronic ... more Published on: 30 May 2016 First PT/INR home self-testing device with Bluetooth technology enabling remote care programmes for anticoagulated patients Roche announced today that it has launched the CoaguChek® INRange system in countries accepting the CE Mark*. more Published on: 27 May 2016 Roche’s Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan in people with previously untreated follicular lymphoma Roche today announced positive results from the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin ... more Published on: 26 May 2016 Reminder: Invitation to Roche Analyst Event at ASCO 2016 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 24 May 2016 Chugai announcement: Avastin approved for additional indication of advanced or recurrent cervical cancer more Published on: 19 May 2016 Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer Roche today announced that Alecensa® , an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death (progression free survival, PFS) by 66 percent compared to ... more Published on: 19 May 2016 FDA grants Roche’s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer Roche today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecentriq® (atezolizumab) for the treatment of people with locally advanced or metastatic ... more Published on: 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Roche today announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 3rd – 7th June in ... more Published on: 29 April 2016 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy ... more Published on: 29 April 2016 CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® ... more Published on: 27 April 2016 Invitation to Roche Analyst Event at ASCO 2016 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 "We have started the year with solid growth in both our Pharmaceuticals and Diagnostics Divisions" more Published on: 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms of multiple sclerosis Roche announced today that new data from three Phase III studies of the investigational medicine OCREVUS™(ocrelizumab) will be presented during the 68th American Academy of Neurology (AAN) Annual ... more Published on: 12 April 2016 Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia Roche announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta™ (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with ... more Published on: 11 April 2016 Reminder: Invitation to Roche's First Quarter Sales 2016 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Tuesday April 19th, 2016. more Published on: 11 April 2016 FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; ... more Published on: 31 March 2016 Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol Roche today announced that the U.S. Food and Drug Administration (FDA) has provided approval to initiate collection and testing of blood samples for screening with the cobas® Zika assay under an ... more Published on: 21 March 2016 Invitation to Roche's First Quarter Sales 2016 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Tuesday April 19th, 2016. more Published on: 15 March 2016 FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; ... more Published on: 1 March 2016 Roche Annual General Meeting 2016 Roche announced today that its shareholders approved all of the Board of Directors' proposals and amendments to the Articles of Incorporation at its ordinary Annual General Meeting (AGM). The 797 ... more Published on: 29 February 2016 FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with ... more Published on: 29 February 2016 Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma Roche today announced top-line results from two phase III studies. The LAVOLTA I-II studies were identical, double-blind, randomised, multicentre, placebo-controlled studies that evaluated the ... more Published on: 26 February 2016 Save the date: Roche Analyst Event at ASCO 2016 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 17 February 2016 U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUS ™) for the treatment of ... more Published on: 10 February 2016 Chugai's ALK Inhibitor "Alecensa" Trial Stopped Early for Benefit Demonstrates Statistically Significant Improvement in PFS in a Japanese Phase III Head to Head Study with Crizotinib more Published on: 28 January 2016 Changes to the Roche Corporate Executive Committee Silvia Ayyoubi (62), Head of Group Human Resources for Roche and member of the Corporate Executive Committee has decided to retire from Roche following the Annual General Meeting in March 2016. more Published on: 28 January 2016 Roche reports strong results in 2015 Commenting on the Group’s results, Roche CEO Severin Schwan said: "2015 was a successful year, with strong business results in both Pharmaceuticals and Diagnostics, driven by our newly launched ... more Published on: 20 January 2016 FDA grants breakthrough therapy designation for investigational medicine venetoclax in combination with MabThera/Rituxan in relapsed or refractory chronic lymphocytic leukaemia Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to venetoclax in combination with MabThera/Rituxan (rituximab) for the treatment of ... more Published on: 15 January 2016 Reminder: Invitation to Roche's Full Year Results 2015 Roche will publish its Full Year Results for 2015 prior to the opening of the Swiss Stock Exchange on Thursday, 28 January 2016. more Published on: 12 January 2016 FDA grants priority review for venetoclax new drug application Roche announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for venetoclax for the treatment of people with chronic ... more Published on: 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Roche today announced updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (MPDL3280A) in people with locally advanced or metastatic ... more Published on: 4 January 2016 Invitation to Roche's Full Year Results 2015 Roche will publish its Full Year Results for 2015 prior to the opening of the Swiss Stock Exchange on Thursday, 28 January 2016. more
Published on: 22 December 2016 Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study Roche today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to ... more
Published on: 21 December 2016 Positive Phase III results for Roche’s investigational medicine OCREVUS® (ocrelizumab) published in New England Journal of Medicine Roche announced today that data from three Phase III studies of its investigational medicine OCREVUS® (ocrelizumab)– the OPERA I and OPERA II studies in relapsing multiple sclerosis (RMS) and the ... more
Published on: 20 December 2016 FDA extends review of application for OCREVUS™ (ocrelizumab) Roche announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics Licence Application (BLA) of ... more
Published on: 16 December 2016 CHMP recommends EU conditional approval of Roche’s Alecensa (alectinib) for people with previously treated ALK-positive NSCLC Roche announced today that the European Medicines Agency (EMA) for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Alecensa® (alectinib) for the treatment of ... more
Published on: 8 December 2016 Roche announces European approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia Roche announced today that the European Commission has granted conditional marketing approval for Venclyxto™ (venetoclax) for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of ... more
Published on: 7 December 2016 Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin ... more
Published on: 5 December 2016 Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan Roche today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva®/Gazyvaro® (obinutuzumab) plus chemotherapy followed by Gazyva/Gazyvaro alone head-to-head against ... more
Published on: 5 December 2016 Changes in Roche Board of Directors At its December meeting, the Board of Directors (BoD) of Roche Holding decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 14 March 2017. more
Published on: 22 November 2016 Reminder: Invitation to Roche Analyst Event at ASH 2016 We are pleased to invite you to an analyst briefing to discuss data presented on Roche Group’s hematology portfolio at the American Society of Hematology Annual Meeting (ASH) in San Diego (3 – 6 ... more
Published on: 15 November 2016 Roche launches imCORE, a global network of cancer immunotherapy centers of excellence Roche today launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the world’s leading scientific and clinical experts in ... more
Published on: 12 November 2016 Phase III GiACTA study shows Roche’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis Roche today announced positive results from the phase III GiACTA study, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). more
Published on: 7 November 2016 Roche announces initiation of two phase III pivotal trials in melanoma based on results of studies combining targeted and immunotherapy treatment approaches; early data presented at the International Congress of the Society for Melanoma Research Roche announced results from two early cancer immunotherapy studies at the International Congress of the Society for Melanoma Research (SMR). more
Published on: 3 November 2016 Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting Roche announced today that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting ... more
Published on: 2 November 2016 Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting Roche today announced that new data from Actemra®/RoActemra® and Rituxan®/MabThera® will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health ... more
Published on: 31 October 2016 Invitation to Roche Analyst Event at ASH 2016 We are pleased to invite you to an analyst briefing to discuss data presented on Roche Group’s hematology portfolio at the American Society of Hematology Annual Meeting (ASH) in San Diego (3 – 6 ... more
Published on: 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increased 4% to CHF 37.5 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 29.1 billion, driven by demand for breast cancer medicines Perjeta and Herceptin as well as for ... more
Published on: 19 October 2016 FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have ... more
Published on: 17 October 2016 FDA approves Lucentis (ranibizumab injection) prefilled syringe Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. more
Published on: 14 October 2016 Roche announces CHMP recommendation for EU approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto™ (venetoclax) for the treatment of people with chronic lymphocytic ... more
Published on: 13 October 2016 Reminder: Invitation to Roche’s 9 Months Sales 2016 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Thursday, 20th October 2016. more
Published on: 11 October 2016 FDA grants priority review to Lucentis (ranibizumab injection) supplemental biologics license application for myopic choroidal neovascularization Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Lucentis® (ranibizumab ... more
Published on: 9 October 2016 Roche’s TECENTRIQ (atezolizumab) shows significant survival advantage compared to chemotherapy regardless of PD-L1 status in a specific type of lung cancer in Phase III study Roche today announced data from the positive, pivotal Phase III OAK study of TECENTRIQ® (atezolizumab) at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting in Copenhagen, Denmark. more
Published on: 5 October 2016 FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra/RoActemra® (tocilizumab) for giant cell arteritis (GCA), a ... more
Published on: 4 October 2016 Save the date: Roche Analyst Event at ASH 2016 We are pleased to invite you to an analyst briefing to discuss data presented on Roche Group’s hematology portfolio at the American Society of Hematology Annual Meeting (ASH) in San Diego (3 – 6 ... more
Published on: 4 October 2016 US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC Roche announced today that it has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib). more
Published on: 3 October 2016 First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Roche today announced that new results from studies with its approved or investigational medicines across more than 20 cancer types will be presented during the European Society for Medical Oncology ... more
Published on: 22 September 2016 Invitation to Roche's Third Quarter Sales 2016 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Thursday, 20th October 2016. more
Published on: 14 September 2016 Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented ... more
Published on: 8 September 2016 Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Index for the eighth year running For the eighth consecutive year, Roche has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry of the Dow Jones Sustainability Index ... more
Published on: 1 September 2016 Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy Roche today announced positive results for TECENTRIQ® from the Phase III study, OAK. more
Published on: 26 August 2016 Anti-Cancer Agent “Xeloda®”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer” more
Published on: 23 August 2016 Roche launches innovative Accu-Chek Guide blood glucose monitoring system, which makes every step of testing easy Roche today announced the launch of the Accu-Chek® Guide, the next-generation blood glucose monitoring system. more
Published on: 28 July 2016 Roche’s emicizumab continued to show promising safety and efficacy profile in long-term study in people with severe haemophilia A Roche announced yesterday new data for investigational haemophilia medicine emicizumab (ACE910) at the World Federation of Hemophilia 2016 World Congress. more
Published on: 27 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more
Published on: 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% at constant exchange rates, 6% in Swiss francs more
Published on: 19 July 2016 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more
Published on: 18 July 2016 Roche provides update on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma Roche today announced that the phase III GOYA study evaluating Gazyva®/Gazyvaro® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated diffuse large B-cell lymphoma ... more
Published on: 14 July 2016 Reminder: Invitation to Roche's Half Year Results 2016 Roche will publish its Half Year Results for 2016 prior to the opening of the Swiss Stock Exchange on 21st July, 2016. more
Published on: 5 July 2016 Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more
Published on: 28 June 2016 Roche's marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Roche announced today that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of OCREVUS® (ocrelizumab) for the treatment of relapsing multiple ... more
Published on: 23 June 2016 Invitation to Roche's Half Year Results 2016 Roche will publish its Half Year Results for 2016 prior to the opening of the Swiss Stock Exchange on 21st July, 2016. more
Published on: 20 June 2016 Roche launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing Roche announced today that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark. more
Published on: 16 June 2016 Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular ... more
Published on: 8 June 2016 Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with ... more
Published on: 7 June 2016 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2016 We are pleased to invite you to an analyst event on Tuesday, 2nd August 2016 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more
Published on: 6 June 2016 Phase III study shows Roche's Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA) Roche today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). more
Published on: 5 June 2016 Roche’s cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer Roche, today announced that in a Phase II study, IMvigor210, Tecentriq® (atezolizumab) shrank tumours (objective response rate, ORR) in 24 percent (n=28) of people with locally advanced or metastatic ... more
Published on: 4 June 2016 Roche showcases three distinct combinations for cancer immunotherapy treatment across a broad range of cancers Roche is presenting data from across its cancer immunotherapy pipeline highlighting its multipronged combination approach to cancer immunotherapy treatment. more
Published on: 4 June 2016 Roche's Tecentriq® (atezolizumab) shows increasing overall survival benefit in updated clinical data analysis for people with specific type of advanced lung cancer Roche will today present updated survival data from the phase II study POPLAR, in people with previously treated advanced non-small cell lung cancer (NSCLC). more
Published on: 31 May 2016 Roche's subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia Roche announced today that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera® (rituximab) for people with previously untreated and relapsed/refractory chronic ... more
Published on: 30 May 2016 First PT/INR home self-testing device with Bluetooth technology enabling remote care programmes for anticoagulated patients Roche announced today that it has launched the CoaguChek® INRange system in countries accepting the CE Mark*. more
Published on: 27 May 2016 Roche’s Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan in people with previously untreated follicular lymphoma Roche today announced positive results from the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin ... more
Published on: 26 May 2016 Reminder: Invitation to Roche Analyst Event at ASCO 2016 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 24 May 2016 Chugai announcement: Avastin approved for additional indication of advanced or recurrent cervical cancer more
Published on: 19 May 2016 Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer Roche today announced that Alecensa® , an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death (progression free survival, PFS) by 66 percent compared to ... more
Published on: 19 May 2016 FDA grants Roche’s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer Roche today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecentriq® (atezolizumab) for the treatment of people with locally advanced or metastatic ... more
Published on: 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Roche today announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 3rd – 7th June in ... more
Published on: 29 April 2016 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy ... more
Published on: 29 April 2016 CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® ... more
Published on: 27 April 2016 Invitation to Roche Analyst Event at ASCO 2016 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 "We have started the year with solid growth in both our Pharmaceuticals and Diagnostics Divisions" more
Published on: 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms of multiple sclerosis Roche announced today that new data from three Phase III studies of the investigational medicine OCREVUS™(ocrelizumab) will be presented during the 68th American Academy of Neurology (AAN) Annual ... more
Published on: 12 April 2016 Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia Roche announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta™ (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with ... more
Published on: 11 April 2016 Reminder: Invitation to Roche's First Quarter Sales 2016 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Tuesday April 19th, 2016. more
Published on: 11 April 2016 FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; ... more
Published on: 31 March 2016 Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol Roche today announced that the U.S. Food and Drug Administration (FDA) has provided approval to initiate collection and testing of blood samples for screening with the cobas® Zika assay under an ... more
Published on: 21 March 2016 Invitation to Roche's First Quarter Sales 2016 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2016 prior to the opening of the Swiss Stock Exchange on Tuesday April 19th, 2016. more
Published on: 15 March 2016 FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; ... more
Published on: 1 March 2016 Roche Annual General Meeting 2016 Roche announced today that its shareholders approved all of the Board of Directors' proposals and amendments to the Articles of Incorporation at its ordinary Annual General Meeting (AGM). The 797 ... more
Published on: 29 February 2016 FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with ... more
Published on: 29 February 2016 Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma Roche today announced top-line results from two phase III studies. The LAVOLTA I-II studies were identical, double-blind, randomised, multicentre, placebo-controlled studies that evaluated the ... more
Published on: 26 February 2016 Save the date: Roche Analyst Event at ASCO 2016 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 17 February 2016 U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUS ™) for the treatment of ... more
Published on: 10 February 2016 Chugai's ALK Inhibitor "Alecensa" Trial Stopped Early for Benefit Demonstrates Statistically Significant Improvement in PFS in a Japanese Phase III Head to Head Study with Crizotinib more
Published on: 28 January 2016 Changes to the Roche Corporate Executive Committee Silvia Ayyoubi (62), Head of Group Human Resources for Roche and member of the Corporate Executive Committee has decided to retire from Roche following the Annual General Meeting in March 2016. more
Published on: 28 January 2016 Roche reports strong results in 2015 Commenting on the Group’s results, Roche CEO Severin Schwan said: "2015 was a successful year, with strong business results in both Pharmaceuticals and Diagnostics, driven by our newly launched ... more
Published on: 20 January 2016 FDA grants breakthrough therapy designation for investigational medicine venetoclax in combination with MabThera/Rituxan in relapsed or refractory chronic lymphocytic leukaemia Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to venetoclax in combination with MabThera/Rituxan (rituximab) for the treatment of ... more
Published on: 15 January 2016 Reminder: Invitation to Roche's Full Year Results 2015 Roche will publish its Full Year Results for 2015 prior to the opening of the Swiss Stock Exchange on Thursday, 28 January 2016. more
Published on: 12 January 2016 FDA grants priority review for venetoclax new drug application Roche announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for venetoclax for the treatment of people with chronic ... more
Published on: 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Roche today announced updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (MPDL3280A) in people with locally advanced or metastatic ... more
Published on: 4 January 2016 Invitation to Roche's Full Year Results 2015 Roche will publish its Full Year Results for 2015 prior to the opening of the Swiss Stock Exchange on Thursday, 28 January 2016. more